Strides Pharma expects recovery in its US business from the second half of FY27 despite a weaker-than-expected flu season impacting recent growth, while reiterating its $375-400 million North America revenue target for FY28. It added that Ex-US markets are emerging as a stronger growth driver and are expected to outpace the US business going ahead.
